Semaglutide demonstrated superior glycaemic control vs insulin glargine U100 in adults with type 2 diabetes

Results from the SUSTAIN 4 trial were presented at the American Association of Clinical Endocrinologists 25th Annual Scientific and Clinical Congress (AACE) in Orlando, US.

The 30-week SUSTAIN 4 trial showed that, from a mean baseline HbA1c of 8.2%, adults with type 2 diabetes receiving metformin with or without sulfonylurea, achieved statistically significant and superior improvements in HbA1c reductions of 1.2% and 1.6% when treated with 0.5 mg and 1.0 mg semaglutide, respectively, vs a 0.8% reduction with insulin glargine U100 (p<0.0001 for both). End of trial mean dose of insulin glargine U100 was 29 IU/day.

”Type 2 diabetes is a complex disease and many patients on insulin are still uncontrolled,” said Vanita Aroda, SUSTAIN 4 investigator and Physician Investigator at the MedStar Health Research Institute, Hyattsville, MD, US. “The results of SUSTAIN 4 are encouraging, as once-weekly semaglutide demonstrated superior glycaemic control compared to insulin glargine U100 in people that generally had a relatively long duration of type 2 diabetes.”